Who Owns Alliance Pharma Company?

Alliance Pharma Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Alliance Pharma?

Understanding a company's ownership is paramount for investors and strategists alike. The recent acquisition of Alliance Pharma SWOT Analysis by Aegros Bidco Limited marks a pivotal moment, transforming this international consumer healthcare company from a publicly traded entity to a privately held one. This shift raises critical questions about the future direction and strategic priorities of Alliance Pharma.

This exploration delves into the evolving ownership structure of the Alliance Pharma company, tracing its history from its inception to its current state. We'll dissect the implications of the DBAY Affiliates and ERES IV Fund acquisition, examining the impact on Alliance Pharma shareholders and the company's strategic trajectory. Furthermore, we'll analyze the composition of the Board of Directors and the dynamics of voting power, providing a comprehensive view of who owns Alliance Pharma and what it means for its future, including its financial performance and key executives.

The specifics of the founders and early ownership of the Alliance Pharma company at its inception in 1996 are not readily available in the provided search results. Information regarding the initial equity split or the backgrounds of the founders is not detailed in the available data. The company's journey began as a UK-focused specialty pharmaceutical business.

The shift from private to public ownership in 2003, when Alliance Pharma was listed, marked a significant change in its ownership structure. This transition is a key point in understanding the evolution of the company's ownership. The provided information does not offer specific details about early agreements, vesting schedules, or initial ownership disputes.

Therefore, the provided information does not offer a comprehensive view of the founders and early ownership details of Alliance Pharma.

Key Points on Early Ownership

The early ownership of Alliance Pharma is not fully documented in the available sources. The company's history includes a transition from private to public ownership, which is a crucial aspect of its ownership structure. For a deeper understanding of the competitive environment, explore the Competitors Landscape of Alliance Pharma.

• The company's public listing in 2003 was a major shift in its ownership.
• Specifics about the founders and initial equity are not available in the provided data.
• The company started as a UK-focused specialty pharmaceutical business.
• Details on early agreements and disputes are not present in the information.

Alliance Pharma SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Alliance Pharma has seen significant changes since its initial public offering (IPO) in 2003. Initially a UK-focused specialty pharmaceutical business, it transitioned to an international consumer healthcare business. By 2023, consumer healthcare brands accounted for 75% of Alliance Group revenues. A major shift occurred when DBAY Advisors Limited became the largest shareholder, starting in December 2022.

The most recent and significant change was the recommended acquisition by Aegros Bidco Limited, announced on January 10, 2025. This entity was indirectly owned by DBAY Affiliates and the ERES IV Fund. The acquisition, valued at approximately £362 million after an increased offer, was approved by shareholders on March 13, 2025, and became effective on May 14, 2025. This resulted in Bidco controlling the entire issued share capital, leading to the suspension of trading of Alliance Shares on AIM on May 14, 2025.

Prior to the acquisition, Alliance Pharma had 21 institutional owners and shareholders as of April 25, 2025, holding a total of 5,940,453 shares. Major institutional shareholders included Dfa Investment Trust Co - The United Kingdom Small Company Series, DFIEX - International Core Equity Portfolio - Institutional Class, and DFA INVESTMENT DIMENSIONS GROUP INC - World ex U.S. Targeted Value Portfolio Institutional Class. For more details on the company's history and evolution, you can read this article about Alliance Pharma.

Key Takeaways on Alliance Pharma Ownership

The ownership of Alliance Pharma has shifted significantly, with DBAY Advisors Limited playing a central role.

• DBAY Affiliates, through Aegros Bidco Limited, now controls the company.
• The acquisition was finalized in May 2025, leading to the delisting of shares.
• Institutional investors held significant stakes prior to the acquisition.
• The company's focus has evolved from pharmaceuticals to consumer healthcare.

Alliance Pharma PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of April 2025, the Board of Directors of the Alliance Pharma company includes several key figures. Camillo Pane serves as the Chair of the Board, appointed on February 19, 2024. Nick Sedgwick is the Chief Executive Officer, having joined on May 13, 2024. Andrew Franklin is the Chief Financial Officer and also a Director. Other independent non-executive directors include Richard Jones, Richard McKenzie, Kristof Neirynck, Eva-Lotta Sjöstedt, and Martin Sutherland.

The composition of the board reflects a recent transition in leadership. This change is significant as the company navigates its strategic direction and operational goals. Understanding the board's structure is crucial for stakeholders, as they oversee the company's performance and strategic decisions. The board's decisions influence the overall direction and financial health of Alliance Pharma.

Prior to its delisting, the voting structure of Alliance Pharma, as a publicly listed company, operated on a one-share-one-vote basis. On June 12, 2024, the company's ordinary issued share capital consisted of 540,399,740 ordinary shares, each with one vote, totaling 540,399,740 voting rights. By June 30, 2024, the total voting rights increased to 540,565,539. The recent acquisition by Aegros Bidco Limited, with DBAY Affiliates as the largest shareholder holding approximately 27.9% of the voting rights, has significantly altered the company's ownership structure. The acquisition by DBAY Affiliates and the ERES IV Fund, with DBAY Affiliates holding 70.1% post-acquisition, will significantly consolidate voting power and control. For more on the target market, see Target Market of Alliance Pharma.

Key Takeaways on Alliance Pharma Ownership

The Board of Directors has recently seen changes, including new appointments for the Chair and CEO. The voting structure has shifted due to the acquisition by DBAY Affiliates.

• Camillo Pane is the current Chair.
• Nick Sedgwick serves as the CEO.
• DBAY Affiliates now hold a significant portion of voting rights.
• The acquisition has moved the company away from public markets.

Alliance Pharma Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership structure of Alliance Pharma has seen significant shifts. Alliance Pharma ownership changed as DBAY Advisors Limited began accumulating shares in December 2022. By June 2024, DBAY Affiliates held approximately 27.96% of the total voting rights, becoming the largest shareholder. This marked a key transition in the company's ownership profile.

The most notable recent development is the acquisition of Alliance Pharma company by Aegros Bidco Limited, a subsidiary indirectly owned by DBAY Affiliates and the ERES IV Fund. The initial offer was 62.5 pence per share, valuing the company at £349.7 million, which was announced in January 2025. This was later increased to 64.75 pence per share, valuing the company at roughly £362 million. Alliance Pharma shareholders approved the takeover on March 13, 2025, with 92% of the voted shares in favor. The acquisition became effective on May 14, 2025, leading to the suspension of trading on AIM and the expected delisting on May 15, 2025. Post-acquisition, DBAY Affiliates will hold 70.1% of Bidco, while the ERES IV Fund will hold 23.9%.

This shift towards private ownership reflects a broader industry trend. The move aims to provide Alliance Pharma with the capital and operational expertise to support its growth ambitions. The company also saw leadership changes, with Nick Sedgwick becoming CEO in May 2024 and Camillo Pane as Non-Executive Chair in February 2024. Furthermore, the company reduced its net debt to £60.1 million by December 31, 2024, down from £91.2 million in 2023, decreasing group leverage to 1.39 times. For more details, you can read about the Growth Strategy of Alliance Pharma.

Who is the CEO of Alliance Pharma?

Nick Sedgwick became the Chief Executive Officer of Alliance Pharma in May 2024.

What is the company's valuation?

The final cash offer valued the company at approximately £362 million, or 64.75 pence per share.

What is the current debt?

The net debt was reduced to £60.1 million at December 31, 2024.

What is the ownership structure post-acquisition?

DBAY Affiliates will hold 70.1% of Bidco, and the ERES IV Fund will hold 23.9%.

Alliance Pharma Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs